Effects of rasagiline on olfactory function in patients with Parkinson's disease. Issue 14 (4th November 2013)

• Record Type: Journal Article
• Authors: Haehner, Antje; Hummel, Thomas; Wolz, Martin; Klingelhöfer, Lisa; Fauser, Mareike; Storch, Alexander; Reichmann, Heinz
• Is Part Of: Movement disorders. Volume 28:Issue 14(2013)
• Page Start: 2023
• Page End: 2027
• Publication Date: 2013-11-04
• Subjects: Movement disorders -- Periodicals; 610
• DOI: 10.1002/mds.25661
• Languages: English
• ISSNs: 0885-3185

Abstract

<abstract abstract-type="main"> <title>ABSTRACT</title> <sec id="mds25661-sec-0001" sec-type="section"> <title>Background</title> <p>Impairment of olfactory function is a well‐recognized nonmotor manifestation of Parkinson's disease (PD). The aim of this investigation was to determine if the MAO‐B inhibitor rasagiline can improve olfaction in PD patients.</p> </sec> <sec id="mds25661-sec-0002" sec-type="section"> <title>Methods</title> <p>Thirty‐four PD patients participated in this single‐center, prospective, randomized, controlled, double‐blind study. Seventeen patients were randomly assigned to rasagiline and 17 patients to placebo. Ortho‐ and retronasal olfactory testing and recording of event‐related potentials were performed before and after 120 days of rasagiline versus placebo intake.</p> </sec> <sec id="mds25661-sec-0003" sec-type="section"> <title>Results</title> <p>When comparing olfactory score differences between baseline and after 120 days between the 2 groups, the level of significance was not reached.</p> </sec> <sec id="mds25661-sec-0004" sec-type="section"> <title>Conclusions</title> <p>The primary end point of the study was not reached, and therefore, a specific effect of rasagiline on olfactory function in PD could not be demonstrated. © 2013 International Parkinson and Movement Disorder Society</p> </sec> </abstract>